News | January 18, 2023
Glenmark to divest select dermatology brands for Rs. 340.48 Cr
The divested brands include Onabet, Halovate, Sorvate, Luligee, Demelan, Aceret, Dosetil, Revize, and Powercort, and their sub-brands
The divested brands include Onabet, Halovate, Sorvate, Luligee, Demelan, Aceret, Dosetil, Revize, and Powercort, and their sub-brands
This donation will allow the continuation of the cycle of vaccination for children foreseen within the national immunization program carried out by the Ministry of Public Health of Cuba
Through the new agreements, Cristal Therapeutics and McSAF will gain access to Lonza’s integrated bioconjugates offering and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates
This DSIR recognition for company's in-house R&D Unit make it eligible for receiving funds for R&D purpose from various government departments and agencies
New facility is based at Lonza’s Bend, Oregon (US) site, a Center of Excellence for bioavailability enhancement
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad, India
Brexpiprazole is an atypical antipsychotic indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults
Launch of Apollo Genomics Institutes would provide genetic counselling, tests, treatment and care for genetic disorders
Collaboration to generate and develop therapeutics for oncology and non-oncology conditions
Febuxostat tablets had annual sales of USD 32 million in the United States according to IQVIA data (IQVIA MAT Sept. 2022).
Subscribe To Our Newsletter & Stay Updated
